Oral and parenteral immunization of chickens (Gallus gallus) against West Nile virus with recombinant envelope protein

Carol Fassbinder-Orth, Erik K. Hofmeister, Carolyn Weeks-Levy, William H. Karasov

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

West Nile virus (WNV) causes morbidity and mortality in humans, horses, and in more than 315 bird species in North America. Currently approved WNV vaccines are designed for parenteral administration and, as yet, no effective oral WNV vaccines have been developed. WNV envelope (E) protein is a highly antigenic protein that elicits the majority of virus-neutralizing antibodies during a WNV immune response. Leghorn chickens were given three vaccinations (each 2 wk apart) of E protein orally (20 μg or 100 μg/dose), of E protein intramuscularly (IM, 20 μg/dose), or of adjuvant only (control group) followed by a WNV challenge. Viremias were measured post-WNV infection, and three new enzyme-linked immunosorbent assays were developed for quantifying IgM, IgY, and IgA-mediated immune response of birds following WNV infection. WNV viremia levels were significantly lower in the IM group than in both oral groups and the control group. Total WNV E protein-specific IgY production was significantly greater, and WNV nonstructural 1-specific IgY was significantly less, in the IM group compared to all other treatment groups. The results of this study indicate that IM vaccination of chickens with E protein is protective against WNV infection and results in a significantly different antibody production profile as compared to both orally vaccinated and nonvaccinated birds.

Original languageEnglish
Pages (from-to)502-509
Number of pages8
JournalAvian Diseases
Volume53
Issue number4
DOIs
StatePublished - 2009

Fingerprint

West Nile virus
Gallus gallus
Recombinant Proteins
Chickens
mouth
Immunization
immunization
chickens
proteins
West Nile Virus Vaccines
Virus Diseases
Birds
Viremia
Proteins
viremia
Vaccination
birds
Viral Envelope Proteins
Control Groups
vaccination

All Science Journal Classification (ASJC) codes

  • Animal Science and Zoology
  • Immunology and Microbiology(all)
  • Food Animals

Cite this

Oral and parenteral immunization of chickens (Gallus gallus) against West Nile virus with recombinant envelope protein. / Fassbinder-Orth, Carol; Hofmeister, Erik K.; Weeks-Levy, Carolyn; Karasov, William H.

In: Avian Diseases, Vol. 53, No. 4, 2009, p. 502-509.

Research output: Contribution to journalArticle

Fassbinder-Orth, Carol ; Hofmeister, Erik K. ; Weeks-Levy, Carolyn ; Karasov, William H. / Oral and parenteral immunization of chickens (Gallus gallus) against West Nile virus with recombinant envelope protein. In: Avian Diseases. 2009 ; Vol. 53, No. 4. pp. 502-509.
@article{6aa72771f5154444b7b2158f76b88bc6,
title = "Oral and parenteral immunization of chickens (Gallus gallus) against West Nile virus with recombinant envelope protein",
abstract = "West Nile virus (WNV) causes morbidity and mortality in humans, horses, and in more than 315 bird species in North America. Currently approved WNV vaccines are designed for parenteral administration and, as yet, no effective oral WNV vaccines have been developed. WNV envelope (E) protein is a highly antigenic protein that elicits the majority of virus-neutralizing antibodies during a WNV immune response. Leghorn chickens were given three vaccinations (each 2 wk apart) of E protein orally (20 μg or 100 μg/dose), of E protein intramuscularly (IM, 20 μg/dose), or of adjuvant only (control group) followed by a WNV challenge. Viremias were measured post-WNV infection, and three new enzyme-linked immunosorbent assays were developed for quantifying IgM, IgY, and IgA-mediated immune response of birds following WNV infection. WNV viremia levels were significantly lower in the IM group than in both oral groups and the control group. Total WNV E protein-specific IgY production was significantly greater, and WNV nonstructural 1-specific IgY was significantly less, in the IM group compared to all other treatment groups. The results of this study indicate that IM vaccination of chickens with E protein is protective against WNV infection and results in a significantly different antibody production profile as compared to both orally vaccinated and nonvaccinated birds.",
author = "Carol Fassbinder-Orth and Hofmeister, {Erik K.} and Carolyn Weeks-Levy and Karasov, {William H.}",
year = "2009",
doi = "10.1637/8688-031009-Reg.1",
language = "English",
volume = "53",
pages = "502--509",
journal = "Avian Diseases",
issn = "0005-2086",
publisher = "American Association of Avian Pathologists",
number = "4",

}

TY - JOUR

T1 - Oral and parenteral immunization of chickens (Gallus gallus) against West Nile virus with recombinant envelope protein

AU - Fassbinder-Orth, Carol

AU - Hofmeister, Erik K.

AU - Weeks-Levy, Carolyn

AU - Karasov, William H.

PY - 2009

Y1 - 2009

N2 - West Nile virus (WNV) causes morbidity and mortality in humans, horses, and in more than 315 bird species in North America. Currently approved WNV vaccines are designed for parenteral administration and, as yet, no effective oral WNV vaccines have been developed. WNV envelope (E) protein is a highly antigenic protein that elicits the majority of virus-neutralizing antibodies during a WNV immune response. Leghorn chickens were given three vaccinations (each 2 wk apart) of E protein orally (20 μg or 100 μg/dose), of E protein intramuscularly (IM, 20 μg/dose), or of adjuvant only (control group) followed by a WNV challenge. Viremias were measured post-WNV infection, and three new enzyme-linked immunosorbent assays were developed for quantifying IgM, IgY, and IgA-mediated immune response of birds following WNV infection. WNV viremia levels were significantly lower in the IM group than in both oral groups and the control group. Total WNV E protein-specific IgY production was significantly greater, and WNV nonstructural 1-specific IgY was significantly less, in the IM group compared to all other treatment groups. The results of this study indicate that IM vaccination of chickens with E protein is protective against WNV infection and results in a significantly different antibody production profile as compared to both orally vaccinated and nonvaccinated birds.

AB - West Nile virus (WNV) causes morbidity and mortality in humans, horses, and in more than 315 bird species in North America. Currently approved WNV vaccines are designed for parenteral administration and, as yet, no effective oral WNV vaccines have been developed. WNV envelope (E) protein is a highly antigenic protein that elicits the majority of virus-neutralizing antibodies during a WNV immune response. Leghorn chickens were given three vaccinations (each 2 wk apart) of E protein orally (20 μg or 100 μg/dose), of E protein intramuscularly (IM, 20 μg/dose), or of adjuvant only (control group) followed by a WNV challenge. Viremias were measured post-WNV infection, and three new enzyme-linked immunosorbent assays were developed for quantifying IgM, IgY, and IgA-mediated immune response of birds following WNV infection. WNV viremia levels were significantly lower in the IM group than in both oral groups and the control group. Total WNV E protein-specific IgY production was significantly greater, and WNV nonstructural 1-specific IgY was significantly less, in the IM group compared to all other treatment groups. The results of this study indicate that IM vaccination of chickens with E protein is protective against WNV infection and results in a significantly different antibody production profile as compared to both orally vaccinated and nonvaccinated birds.

UR - http://www.scopus.com/inward/record.url?scp=73449134485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73449134485&partnerID=8YFLogxK

U2 - 10.1637/8688-031009-Reg.1

DO - 10.1637/8688-031009-Reg.1

M3 - Article

VL - 53

SP - 502

EP - 509

JO - Avian Diseases

JF - Avian Diseases

SN - 0005-2086

IS - 4

ER -